Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
2022 · New England Journal of Medicine · 2,396 citations
https://doi.org/10.1056/nejmoa2203690
T
Tao Sun
Wuhan University(CN)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
345
Papers
11.1K
Citations
43
h-index
154
i10-index
Tao Sun is an academic researcher from Wuhan University. The author has contributed to research in topics: Advanced Breast Cancer Therapies & Neuroscience and Neuropharmacology Research & HER2/EGFR in Cancer Research. The author has an h-index of 43, co-authored 294 publications.
ORCID: 0000-0001-8062-3432Papers by this author
worksAmivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
2023 · Annals of Oncology · 347 citations
https://doi.org/10.1016/j.annonc.2023.10.117
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial
2019 · The Lancet Oncology · 261 citations
https://doi.org/10.1016/s1470-2045(19)30164-0
MicroRNA-532-3p regulates mitochondrial fission through targeting apoptosis repressor with caspase recruitment domain in doxorubicin cardiotoxicity
2015 · Cell Death and Disease · 117 citations
https://doi.org/10.1038/cddis.2015.41
Oncogenic driver genes and tumor microenvironment determine the type of liver cancer
2020 · Cell Death and Disease · 114 citations
https://doi.org/10.1038/s41419-020-2509-x
MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer
2021 · Future Oncology · 91 citations
https://doi.org/10.2217/fon-2021-0923
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat